© 2023 BioMarin. All rights reserved.

Investors & Media
Stock Quote
Transforming Lives Through Genetic Discovery

We seek to make a big difference in genetic disorders. At BioMarin, through our unparalleled expertise in genetics and molecular biology, we will continue to develop targeted therapies that address the root cause of the conditions we seek to treat. Applying our knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most.

Fast Facts

>$2 Billion

in 2022 FY Total Revenues

78 Countries

Commercial Footprint

World-class Capabilities

Manufacturing, R&D, Regulatory, and Commercial

"Core 4" Product Framework

Genetic, Targeted, Assessable, Transformational

Latest News
Mar 14, 2023

New Analyses from Phase 2 and Phase 3 Extension Studies Continue to Demonstrate Sustained Improvement in Growth with no Change in Safety Profile SAN RAFAEL, Calif., March 14, 2023 /PRNewswire/ --...

Mar 7, 2023

The Supplemental New Drug Application is Based on Positive Results from Global Randomized Phase 2 Study in Infants and Young Children FDA set PDUFA Target Action Date of October 21, 2023 SAN...

Mar 6, 2023

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that it received notice this afternoon from...

All Press Releases

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.


Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.


Learn More


Our executive team is made up of tech leaders with diverse backgrounds and a singular focus.



Contact Us

Investor Relations

Media & Press

Email Alerts

Sign up for alerts to receive updates on company announcements, financial information and more!